# BPC-157 FAQ: Side Effects, Safety, Legal Status, and More

> BPC-157 FAQ: direct, cited answers on side effects, liver and kidney safety, heart effects, onset, legal status and 503A compounding — grounded in the preclinical record and the three human pilots.

Direct answers to the common BPC-157 questions, each tied to a study where the claim is quantitative, and each honest where the human data is absent.

## BPC-157 side effects in the research literature

BPC-157 side effects are not well characterized in humans, because the human dataset is three small pilots and none was designed to map a side-effect profile. The 2-person IV safety pilot reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [9]; the 12-patient intravesical pilot reported no adverse events [11]. Those are reassuring within a tiny dataset, not a safety profile.

The candid summary is the one the 2025 narrative review reaches: reported safety is reassuring within the small human dataset and the animal work, but the absence of long-term, large-N human safety data means the safety profile is genuinely unknown [10]. A frequently noted theoretical consideration is that BPC-157 is pro-angiogenic in models [3] — the literature flags this without establishing any causal harm. The honest answer foregrounds the gap rather than the reassurance.

---

The BPC-157 record projected at depth — the cited preclinical findings held on the near plane, the three human pilots a plane back, and the long-term-safety void left dim at the far edge; no clinic behind the projection and nothing here prescribed or sold.